A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.

Cancer Drug Reimbursement Study Could Ramp Up Pressure on 340B Hospitals

A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.

The study by health economics and public health researchers at the University of California at Berkeley found that prices paid in 2019 by Blue Cross Blue Shield health plans in hospital outpatient departments were double those paid in physician offices for biologics, chemotherapies, and other infused cancer drugs (99–104% higher) and for infused hormonal therapies (68% higher).

A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report